Search results for "ACUTE MYELOGENOUS LEUKEMIA"

showing 4 items of 4 documents

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myel…

2007

Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pt…

MaleMyeloidTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationBiochemistryGastroenterologyRecurrenceRisk FactorsUNRELATED DONORSLiving DonorsMedicineTOTAL-BODYACUTE MYELOGENOUS LEUKEMIAHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyCOLONY-STIMULATING FACTORMiddle AgedChemotherapy regimenSurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureFemalePOSTREMISSION THERAPYAdultmedicine.medical_specialtyAcute myeloblastic leukemiaAdolescentImmunologymacromolecular substancesDisease-Free SurvivalMeta-Analysis as TopicInternal medicineotorhinolaryngologic diseasesHumansTransplantation HomologousSurvival rateRetrospective StudiesEUROPEAN GROUPbusiness.industryACUTE MYELOBLASTIC-LEUKEMIACell Biologymedicine.diseaseBONE-MARROW-TRANSPLANTATIONINTENSIVE CHEMOTHERAPYSurgeryTransplantationAML-10 TRIALbusinessFollow-Up StudiesBlood
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

A multicenter, randomized trial of posaconazole (POS) vs fluconazole (FLU) or itraconazole (ITZ) for prophylaxis of invasive fungal infections (IFIs)…

2006

Posaconazolemedicine.medical_specialtyTransplantationAcute myelogenous leukemia (AML)Itraconazolebusiness.industryvirusesvirus diseasesIntensive chemotherapyHematologymedicine.diseaselaw.inventionRandomized controlled triallawInternal medicineImmunologymedicinebusinessFluconazolemedicine.drugBiology of Blood and Marrow Transplantation
researchProduct

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotep…

2021

ABSTRACT One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impa…

medicine.medical_specialtyTransplantation ConditioningPredictive transplantation scoresCyclophosphamideAcute myelogenous leukemiaGraft vs Host DiseaseThioTEPAInternal medicinemedicineHumansImmunology and AllergyBusulfanCyclophosphamideTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationCell BiologyHematologyHaploidentical transplantation with TBF conditioningTacrolimusFludarabineTransplantationsurgical procedures operativeMolecular MedicinebusinessThiotepaVidarabineBusulfanmedicine.drugTransplantation and Cellular Therapy
researchProduct